Penpulimab
Various Cancers
Key Facts
About Hansoh Pharma
Hansoh Pharma's mission is to develop and deliver innovative, high-quality medicines that address significant unmet medical needs in China and worldwide. The company has achieved a dominant position as one of China's most valuable pharmaceutical entities, built upon the commercial success of flagship products and a rich pipeline of novel candidates. Its strategy leverages a fully integrated platform from discovery to commercialization, with a sharp focus on oncology and CNS disorders, while actively pursuing strategic global partnerships to expand its international footprint. Hansoh's substantial R&D investment and manufacturing scale underpin its ambition to become a global biopharmaceutical leader.
View full company profileOther Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| Oncology Immunotherapy Programs | Therapeutic Solutions International | Pre-clinical |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |